BioPharma Resources

Drug Trial Radar · NCT07216703

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,023 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,023

Planned (sponsor's estimate)

Start

Jan 19, 2026

Primary completion

Oct 29, 2031

Study completion Oct 29, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation
First posted
Oct 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment

Conditions

  • Cervical Cancer

Interventions

  • PembrolizumabBiological

    Intravenous (IV) Infusion

  • Sacituzumab TirumotecanBiological

    IV Infusion

  • BevacizumabBiological

    IV Infusion

  • PaclitaxelDrug

    IV Infusion

  • CisplatinDrug

    IV Infusion

  • CarboplatinDrug

    IV Infusion

  • Rescue MedicationsDrug

    Participants will receive the following rescue medications prior to sac-TMT infusion, per approved product label: histamine-1 receptor antagonist, histamine-2 receptor antagonist, acetaminophen or equivalent, and dexamethasone or equivalent, prophylactic steroid mouthwash (dexamethasone or equivalent), and granulocyte colony-stimulating factor (G-CSF).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 Safety Run-in: Number of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 69 months
  2. Part 1 Safety Run-in: Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 66 months
  3. Part 2 Maintenance Treatment: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 48 months
  4. Part 2 Maintenance Treatment: Overall Survival (OS)Time frame: Up to approximately 60 months

Locations

189 sites in 29 countries. Site status is shown where the registry gives one.

  • University of Alabama- Birmingham ( Site 5015)

    Birmingham, Alabama · Recruiting

  • Alaska Womens Cancer Care ( Site 5046)

    Anchorage, Alaska · Recruiting

  • CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 5037)

    Irvine, California · Recruiting

  • Moores Cancer Center-Clinical Trials Office - Gynecological Oncology ( Site 5000)

    La Jolla, California · Recruiting

  • University of California Irvine Medical Center ( Site 6006)

    Orange, California · Recruiting

  • Florida Cancer Specialists - South ( Site 7001)

    Fort Myers, Florida · Recruiting

  • Mount Sinai Braman Comprehensive Cancer Center ( Site 5043)

    Miami Beach, Florida · Recruiting

  • Moffit Cancer Center ( Site 5026)

    Tampa, Florida · Recruiting

  • Florida Cancer Specialists - East ( Site 7000)

    West Palm Beach, Florida · Recruiting

  • Winship Cancer Institute of Emory University ( Site 5005)

    Atlanta, Georgia · Recruiting

  • Nancy N. & J.C. Lewis Cancer and Research Pavillion - Research Department ( Site 6005)

    Savannah, Georgia · Recruiting

  • TRIALS 365 ( Site 6008)

    Shreveport, Louisiana · Recruiting

  • Maryland Oncology Hematology (MOH) ( Site 8001)

    Columbia, Maryland · Recruiting

  • Minnesota Oncology Hematology, PA ( Site 8003)

    Edina, Minnesota · Recruiting

  • Nebraska Methodist Hospital ( Site 5010)

    Omaha, Nebraska · Recruiting

  • Women's Cancer Center of Nevada ( Site 6011)

    Las Vegas, Nevada · Recruiting

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 5039)

    Mineola, New York · Recruiting

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6009)

    New York, New York · Recruiting

  • University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 5020)

    Cincinnati, Ohio · Recruiting

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6002)

    Columbus, Ohio · Recruiting

  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 6001)

    Tulsa, Oklahoma · Recruiting

  • Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8007)

    Eugene, Oregon · Recruiting

  • Honickman Center ( Site 5033)

    Philadelphia, Pennsylvania · Recruiting

  • Asplundh Cancer Pavilion ( Site 5002)

    Willow Grove, Pennsylvania · Recruiting

  • Women & Infants Hospital ( Site 6003)

    Providence, Rhode Island · Recruiting

  • University of Tennessee Medical Center ( Site 6012)

    Knoxville, Tennessee · Recruiting

  • Texas Oncology - DFW ( Site 8005)

    Fort Worth, Texas · Recruiting

  • Houston Methodist Hospital-Obstetrics and Gynecology ( Site 6010)

    Houston, Texas · Recruiting

  • Texas Oncology-The Woodlands ( Site 8000)

    The Woodlands, Texas · Recruiting

  • Texas Oncology - Northeast Texas ( Site 8002)

    Tyler, Texas · Recruiting

  • University of Virginia Cancer Center ( Site 5044)

    Charlottesville, Virginia · Recruiting

  • Inova Schar Cancer Institute ( Site 5045)

    Fairfax, Virginia · Recruiting

  • Centro Medico Privado CEMAIC ( Site 0102)

    Córdoba, Argentina · Recruiting

  • Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0111)

    La Rioja, Argentina · Recruiting

  • Centro de Oncología e Investigación de Buenos Aires ( Site 0107)

    Berazategui, Buenos Aires, Argentina · Recruiting

  • Instituto de Investigaciones Clinicas Mar del Plata ( Site 0105)

    Mar del Plata, Buenos Aires, Argentina · Recruiting

  • Fundación Respirar ( Site 0101)

    Belgrano, Buenos Aires F.D., Argentina · Recruiting

  • Instituto Misionero del Cancer ( Site 0112)

    Posadas, Misiones Province, Argentina · Recruiting

  • Instituto de Oncologia de Rosario ( Site 0104)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Hospital Provincial del Centenario ( Site 0106)

    Rosario, Santa Fe Province, Argentina · Recruiting

Showing 40 of 189 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.